Sugi Predict

Sugi Predict / Compounds / SCHEMBL191310

SCHEMBL191310

SCHEMBL191310

CC(C)(C)OC(=O)N[C@@H](CCO[Si](C)(C)C(C)(C)C)C(=O)O

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ CTSK P43235 7/20 0.43
▸ CTSS P25774 5/20 0.43
▸ ITGB3 P05106 1/20 0.43
▸ ITGA2B P08514 1/20 0.43
▸ PPARA Q07869 7/20 0.41
▸ PPARG P37231 6/20 0.41
▸ ITGAV P06756 1/20 0.40
▸ ITGB6 P18564 1/20 0.40
▸ MEN1 O00255 1/20 0.40
▸ GAA P10253 1/20 0.40
▸ KMT2A Q03164 1/20 0.40
▸ CTSL P07711 1/20 0.40
▸ CTSB P07858 1/20 0.40
▸ ACE P12821 1/20 0.40
▸ PPARD Q03181 2/20 0.39
▸ ALDH1A1 P00352 1/20 0.38
▸ TSHR P16473 1/20 0.38
▸ IDO1 P14902 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL490696 1.00 CTSK (0.43) CTSKCTSSITGB3ITGA2BPPARA
SCHEMBL191311 1.00 CTSK (0.43) CTSKCTSSITGB3ITGA2BPPARA
SCHEMBL28821394 0.92 CTSK (0.45) CTSKCTSSITGB3ITGA2BPPARA
SCHEMBL28821396 0.92 CTSK (0.45) CTSKCTSSITGB3ITGA2BPPARA
SCHEMBL29548094 0.90 CTSK (0.41) CTSKCTSSITGB3ITGA2BMEN1
SCHEMBL26968991 0.90 CTSK (0.41) CTSKCTSSITGB3ITGA2BMEN1
SCHEMBL19080575 0.89 CTSK (0.40) CTSKCTSSITGB3ITGA2BCTSL
SCHEMBL865794 0.88 FOLH1 (0.35) CTSKCTSSITGB3ITGA2BITGAV
SCHEMBL865793 0.88 FOLH1 (0.35) CTSKCTSSITGB3ITGA2BITGAV
SCHEMBL23177271 0.87 CTSK (0.42) CTSKCTSSITGB3ITGA2BCTSL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 111 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12384797-B2 Thioeno[3,2-b] pyridin-7-amine compounds for treating familial dysautonomia PTC THERAPEUTICS, INC. (US) 2025-08-12 — — US disclosed
EP-3917527-B1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC (US) 2025-04-23 — — EP disclosed
CN-113645971-B Compounds and uses thereof 福宏治疗公司 2024-10-18 — — CN disclosed
CN-112574189-B EP300/CBP inhibitor 海创药业股份有限公司 2024-05-31 — — CN disclosed
EP-4198029-A1 INHIBITORS OF PEPTIDYL ARGININE DEIMINASE (PAD) ENZYMES AND USES THEREOF University Health Network (CA) 2023-06-21 — — EP disclosed
EP-4198029-A1 INHIBITORS OF PEPTIDYL ARGININE DEIMINASE (PAD) ENZYMES AND USES THEREOF University Health Network (CA) 2023-06-21 — — EP disclosed
US-20230079819-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-03-16 — — US disclosed
US-20230057568-A1 COMPOUNDS FOR TREATING FAMILIAL DYSAUTONOMIA PTC THERAPEUTICS, INC. (US) 2023-02-23 — — US disclosed
US-20230057568-A1 COMPOUNDS FOR TREATING FAMILIAL DYSAUTONOMIA PTC THERAPEUTICS, INC. (US) 2023-02-23 — — US disclosed
US-20230027088-A1 EP300/CBP INHIBITOR HINOVA PHARMACEUTICALS INC. (CN) 2023-01-26 — — US disclosed
US-20090131461-A1 Quinoline and quinoxaline derivatives as inhibitors of kinase enzymatic activity CHROMA THERAPEUTICS LTD. (GB) 2009-05-21 — — US disclosed
EP-2016055-A1 INHIBITORS OF P38 MAP KINASE Chroma Therapeutics Limited (GB) 2009-01-21 — — EP disclosed
EP-1964577-A2 Alpha aminoacid ester-drug conjugates hydrolysable by carboxylesterase Chroma Therapeutics Limited (GB) 2008-09-03 — — EP disclosed
EP-1964578-A2 Alpha aminoacid ester-drug conjugates hydrolysable by carboxylesterase Chroma Therapeutics Limited (GB) 2008-09-03 — — EP disclosed
EP-1877366-A1 HYDROXAMIC ACID DERVICATIVES AS INHIBITORS OF HDAC ENZYMATIC ACTIVITY Chroma Therapeutics Limited (GB) 2008-01-16 — — EP disclosed
EP-1877098-A2 ALPHA AMINOACID ESTER-DRUG CONJUGATES HYDROLYSABLE BY CARBOXYLESTERASE Chroma Therapeutics Limited (GB) 2008-01-16 — — EP disclosed
WO-2007129036-A1 INHIBITORS OF P38 MAP KINASE CHROMA THERAPEUTICS LTD. (GB) 2007-11-15 — — WO disclosed
WO-2007129020-A1 PYRIMIDINE DERIVATIVES USEFUL AS DHFR INHIBITORS CHROMA THERAPEUTICS LTD. (GB) 2007-11-15 — — WO disclosed
WO-2006117567-A2 ALPHA AMINOACID ESTER-DRUG CONJUGATES HYDROLYSABLE BY CARBOXYLESTERASE CHROMA THERAPEUTICS LTD (GB) 2006-11-09 — — WO disclosed
WO-2006117548-A1 HYDROXAMIC ACID DERVICATIVES AS INHIBITORS OF HDAC ENZYMATIC ACTIVITY CHROMA THERAPEUTICS LTD (GB) 2006-11-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230057568-A1 COMPOUNDS FOR TREATING FAMILIAL DYSAUTONOMIA SNRPB2, SYNCRIP, HNRNPUL2 CTSK 4312/4885CTSS 4150/4885ITGB3 4095/4885
US-20230079819-A1 COMPOUNDS AND USES THEREOF VHL, CLN6, TFEB CTSK 2434/4885CTSS 2010/4885ITGB3 2416/4885
US-20230027088-A1 EP300/CBP INHIBITOR EP300, MLLT1, CREBBP CTSK 3493/4885CTSS 3589/4885ITGB3 2930/4885
US-20090131461-A1 Quinoline and quinoxaline derivatives as inhibitors of kinase enzymatic activity CDK1, AURKC, CSNK1G3 CTSK 622/4885CTSS 798/4885ITGB3 3942/4885
US-12384797-B2 Thioeno[3,2-b] pyridin-7-amine compounds for treating familial dysautonomia SF3B5, SF3B2, SF3B1 CTSK 4597/4885CTSS 4459/4885ITGB3 3996/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.